<img alt="" src="https://secure.intelligent-consortium.com/791519.png" style="display:none;">

Psomagen tests proteomics service performance — Experimental correlation across sites

Psomagen Blog

Psomagen tests proteomics service performance — Experimental correlation across sites


In multiomics research, it is important to achieve consistent results across laboratories, operators, and machines. Psomagen participated in a concordance test of the Olink® Proteomics Target 48 Cytokine panel. This test ensured that samples processed at our labs achieved similar results to those processed at the Olink® Proteomics lab in Boston. 

Twenty samples with varying cytokine concentration levels were analyzed at the Olink lab, then frozen and shipped to Psomagen for analysis. Results were overwhelmingly positive, with Psomagen reporting: 

  • 0.958 Spearman correlation across all assays
  • 42 out of 45 samples indicating good or excellent reliability with an Intraclass Correlation Coefficient measurement

These results show that Olink® Target 48 can be implemented consistently and accurately with appropriate training in verified service provider facilities. Psomagen has earned a Gold badge for our Olink® Target service, as well as for Olink® Flex and Focus. We were the first North American facility to obtain a Platinum badge for Olink® Explore.

About Psomagen
Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.

Harold Nuñez
Business Development 
301-251-1007 x531

About Olink
Olink Proteomics AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink Proteomics provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st-century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America, and Asia. Olink Proteomics is headquartered in Uppsala, Sweden.